arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Oncology Institute, Inc.

TOI
$5.12 0.00 (0.00%) at close
Industrials ·Services-Offices & Clinics of Doctors of Medicine ·USServices-Offices & Clinics of Doctors of Medicine
26 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
38
Health
Weak
Moderately Bearish
auto_awesome

Analytical Summary

Oncology Institute, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $521.2M
Dividend Yield
Revenue Growth 41.2%
Op. Margin -4.4%
ROIC -10.4%
FCF / Share $-0.03
Trailing P/E
Price / Book
FCF Yield
Debt / Equity -4.83
info Valuation on last close. End-of-day price, Aug 3, 2026.

26-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$147.44M
↑ +41.2%
Net Income Profit after all expenses
$-2.49M
↑ +87.3%
Operating Margin Operating profit as % of sales
-4.4%
↑ +9.2% 18th
FCF / Share Free cash flow per share
$-0.03
↑ +53.6%
Long-Term Debt Long-term obligations
$78.61M
↑ +1.6%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
16
Financial Health
66
Cash Quality
38

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters